Rathbones Group PLC Sells 396,518 Shares of DexCom, Inc. $DXCM

Rathbones Group PLC lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 690,351 shares of the medical device company’s stock after selling 396,518 shares during the period. Rathbones Group PLC owned about 0.18% of DexCom worth $60,261,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of DexCom by 10.2% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,089,385 shares of the medical device company’s stock valued at $95,092,000 after buying an additional 100,607 shares during the last quarter. Aviva PLC lifted its stake in shares of DexCom by 6.8% in the 2nd quarter. Aviva PLC now owns 291,462 shares of the medical device company’s stock valued at $25,442,000 after acquiring an additional 18,667 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in DexCom by 313.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 1,296,814 shares of the medical device company’s stock valued at $113,199,000 after acquiring an additional 983,018 shares during the period. Summit Investment Advisors Inc. boosted its holdings in DexCom by 2.2% during the 1st quarter. Summit Investment Advisors Inc. now owns 16,584 shares of the medical device company’s stock valued at $1,133,000 after acquiring an additional 351 shares during the period. Finally, AE Wealth Management LLC grew its position in DexCom by 50.5% during the 2nd quarter. AE Wealth Management LLC now owns 24,701 shares of the medical device company’s stock worth $2,156,000 after acquiring an additional 8,283 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,383 shares of company stock worth $434,274 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent research reports. Morgan Stanley boosted their price objective on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Piper Sandler set a $75.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Mizuho increased their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, October 24th. Finally, Raymond James Financial boosted their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.86.

DexCom Stock Performance

Shares of DXCM stock opened at $55.00 on Friday. The firm has a market capitalization of $21.45 billion, a price-to-earnings ratio of 38.19, a PEG ratio of 1.43 and a beta of 1.40. The stock has a fifty day moving average of $69.24 and a 200 day moving average of $77.65. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the prior year, the business earned $0.45 EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.